Market Place
Sourcing Support
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
27 Dec 2023 //
BUSINESSWIRE
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Cyclo and Applied Molecular Transport Enter into a Definitive Merger Agreement
21 Sep 2023 //
BUSINESSWIRE
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Applied Molecular Transport Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
AMT lays off further 57% of staff, seeks strategic alternatives
28 Mar 2023 //
FIERCE BIOTECH
Applied Molecular Transport Announces Corporate Leadership Change
27 Mar 2023 //
GLOBENEWSWIRE
After slimming R&D, AMT no closer to taking UC drug into phase 3
10 Mar 2023 //
FIERCE BIOTECH
Applied Molecular Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
Applied Molecular Presents Data from Oral AMT-101 Phase 2 FILLMORE Trial
03 Mar 2023 //
GLOBENEWSWIRE
Applied Molecular Transport Announces FDA Orphan Drug Designation to AMT-101
10 Nov 2022 //
GLOBENEWSWIRE
Applied Molecular Transport to Present at Upcoming November Investor Conferences
08 Nov 2022 //
GLOBENEWSWIRE
Applied Molecular Transport Reports 3Q 2022 Financial Results Provides Corporate
07 Nov 2022 //
GLOBENEWSWIRE
Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD
20 Sep 2022 //
GLOBENEWSWIRE
Applied Molecular Transport Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Applied Molecular Transport’s UC drug hits a roadblock
07 Jul 2022 //
FIERCEBIOTECH
Applied Molecular Transport to Report Top-line PII Results of Oral AMT-101
05 Jul 2022 //
GLOBENEWSWIRE
Applied Molecular Transport to Present at Upcoming June Investor Conferences
02 Jun 2022 //
GLOBENEWSWIRE
Applied Molecular Transport co-founder exits amid 40% staff cut
19 May 2022 //
FIERCEBIOTECH
Applied Molecular Transport Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Applied Molecular Transport to Present at BofA Securities 2022 Conference
05 May 2022 //
GLOBENEWSWIRE
Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE
25 Apr 2022 //
GLOBENEWSWIRE
Applied Molecular Transport Announces Positive Top-line Ph2 ResultsOral AMT-101
25 Apr 2022 //
GLOBENEWSWIRE
Applied Molecular Transport Announces Publication in Tissue Barriers
13 Apr 2022 //
GLOBENEWSWIRE
Applied Molecular Transport Reports Q4 and Full Year 2021 Financial Results
24 Feb 2022 //
GLOBENEWSWIRE
Applied Molecular to Present at SVB Leerink Virtual 11th Annual Conference
10 Feb 2022 //
GLOBENEWSWIRE
Applied Molecular Transport Announces Board Appointments
27 Jan 2022 //
GLOBENEWSWIRE
Applied Molecular Transport to Host Virtual Research & Development Day
11 Oct 2021 //
GLOBENEWSWIRE
Applied Molecular Transport Announces Upcoming Investor Events
17 Sep 2021 //
GLOBENEWSWIRE
Applied Molecular Transport Appoints Holly Schachner to its Board of Directors
24 Aug 2021 //
GLOBENEWSWIRE
Applied Molecular Presents Additional Positive Data from Oral AMT-101 Phase 1b
09 Jul 2021 //
GLOBENEWSWIRE
Applied DNA Adds First Summer Camp for safeCircle Pooled COVID-19 Surveillance
03 Jun 2021 //
BIOSPACE
Applied Molecular Transport Announces Proposed Public Offering of Common Stock
29 Mar 2021 //
BIOSPACE
Applied Molecular Transport Reports Fourth Quarter and Full Year 2020
19 Mar 2021 //
GLOBENEWSWIRE
Applied Molecular Transport Expands Clinical Pipeline & Announces First Subject
01 Mar 2021 //
BIOSPACE
Applied Molecular Transport Announces Publication of Preclinical Data (AMT-101)
10 Nov 2020 //
GLOBENEWSWIRE
Applied Molecular Transport prices upsized IPO at $14, the high end of the range
05 Jun 2020 //
NASDAQ
